30 C
Vientiane
Saturday, June 7, 2025
spot_img
Home Blog Page 130

Marketplace Battle Heats Up: Trust, Convenience and Choice Key as Pricing Pressures Grow

MELBOURNE , Australia, May 22, 2025 /PRNewswire/ — An exclusive Australian study by global ecommerce accelerator, Pattern, has shown that product range, convenience, and trustworthiness will be critical battlegrounds for online marketplaces in 2025.

Jhon - stock.adobe.com
Jhon – stock.adobe.com

With international tariffs reshaping marketplace business models, platforms like Temu and Shein, once known for ultra-cheap products, are now raising their prices. In some markets, the cost of goods such as health and beauty products has surged by 51%.

“The days of marketplaces winning Australian consumers with ultra-cheap pricing alone are over. Although leading platforms like Amazon will continue to attract shoppers with competitive pricing, consumers are now making purchasing decisions based on factors like credibility, product variety and ease-of-shopping,” said Merline McGregor, Managing Director for Pattern Australia.

Convenience Drives Loyalty

Australians are increasingly choosing marketplaces that offer greater convenience. Amazon continues to set the benchmark, with 57% of shoppers rating it as the most convenient platform for purchasing goods, driven by its streamlined ordering process, fast shipping options, and integrated returns experience.

While Shein and Temu have experienced rapid growth in overall shopper awareness, their convenience ratings are significantly lower at 14% and 27%, respectively. This gap highlights a critical challenge for emerging platforms: while aggressive marketing and discounting can attract first-time buyers, delivering a seamless, reliable shopping experience is crucial to securing repeat business.

“Convenience is more than just speed of delivery, it’s about every touchpoint of the shopping experience, extending from intuitive search functions to reliable customer service and simple returns,” said McGregor. “Australian brands selling on marketplaces that deliver frictionless shopping experiences are more likely to secure both the first purchase and increase their chances of building customer loyalty.”

Trustworthiness and Reliability Build Customer Relationships

As price advantages decline, product quality and reliable return processes are key differentiators for marketplaces. Amazon leads in both areas, with 60% of Australian shoppers trusting it for product quality and 53% for reliable returns.

eBay also performs strongly, earning trust from 42% of shoppers, while Kogan lags at 16% and MyDeal at just 9%. Chinese marketplaces, Temu and Shein face even greater challenges, with only 12% and 11% of consumers expressing confidence in the quality of the products they sell.

“In an increasingly competitive and regulated environment, trust is not an aspiration. Marketplaces must consistently deliver quality products, backed by hassle-free returns to build enduring customer relationships,” said McGregor. “We’ve seen a positive improvement in returns processes for all marketplaces, with only 3% of Australian consumers stating they do not trust any marketplace for reliable returns. This is a huge drop from 18% in 2024 and shows that all platforms are prioritising improving the customer experience in this critical area.”

Amazon, eBay and Temu Win with Product Variety 

Amazon is recognised by 60% of shoppers as having the widest variety of inventory in Australia across categories such as electronics, home & kitchen and sporting goods. eBay also retains a strong position, with 45% of consumers recognising its broad range, particularly in the second-hand and collectible markets.

Only 32% of shoppers believe Temu offers the widest product range, yet the number of consumers visiting the platform for its vast product range has surged 87% since 2024.

“A broad and evolving product range is proving key for marketplaces to retain and grow their shopper base. Consumers are moving towards platforms that offer a one-stop-shop experience, and marketplaces that can deliver this effectively across multiple categories have a clear competitive edge,” concluded McGregor.

For more information and to download the full report please click here: ‘2025 Marketplace Consumer Report

RD Technologies Celebrates Passage of Stablecoins Ordinance in Hong Kong

HONG KONG, May 22, 2025 /PRNewswire/ — RD Technologies, a Hong Kong-based fintech leader revolutionizing global payments through blockchain technology, warmly welcomes the Legislative Council’s passage of the Stablecoins Bill on May 21, 2025. This landmark legislation establishes a licensing regime for fiat-referenced stablecoin (FRS) issuers in Hong Kong, enhancing the regulatory framework for virtual asset activities while fostering financial stability and innovation.

The Stablecoins Ordinance requires entities issuing FRS in Hong Kong, or issuing FRS linked to the Hong Kong dollar, to obtain a license from the Hong Kong Monetary Authority (HKMA). Licensees must adhere to stringent requirements, including proper reserve asset management, robust stabilization mechanisms, and processing redemption requests at par value under reasonable conditions. The ordinance also mandates compliance with anti-money laundering, counter-terrorist financing, risk management, disclosure, and auditing standards, ensuring greater protection for the public and investors.

RD Technologies is proud to highlight that its subsidiary, RD InnoTech Limited, the issuer of HKDR, was among the first batch of companies admitted to the HKMA’s stablecoin issuer sandbox in July last year. The admission underscores regulator’s recognition of RD Technologies’ commitment to regulatory compliance and innovation in the stablecoin sector.

“We are thrilled with the passage of the Stablecoins Ordinance, which sets a clear and robust framework for the sustainable growth of Hong Kong’s virtual asset ecosystem as a global financial hub,” said Rita Liu, CEO of RD Technologies. “As pioneers in the stablecoin space, with RD InnoTech Limited’s participation in the HKMA’s sandbox, we are dedicated to building trust by aligning with these regulations to deliver secure and innovative solutions for virtual asset trading, cross-border payments, and tokenization of real-world assets.”

The ordinance, expected to take effect later this year, includes transitional arrangements to allow industry players sufficient time to comply with licensing requirements. RD Technologies remains committed to collaborating with regulators to meet these standards and drive responsible and exciting development in the virtual asset industry.

About RD Technologies Group:

RD Technologies Group (RD Technologies) is the financial platform that bridges the Web2 and Web3 worlds. It deploys innovative fintech to build a business world interconnected by trust. Based in Hong Kong and connected with the global community, RD Technologies was born out of a mission to enable businesses to gain easier access to financial services, enhance trade efficiency, and promote the development of Hong Kong as a trade hub in Asia and an international financial centre. For details: https://rd.group

HKDR Stablecoin (HKDR):

HKDR Stablecoin (HKDR) is a trusted and transparent Hong Kong Dollar stablecoin 1:1 backed by the Hong Kong dollar, with high-quality and highly liquid assets safekept in segregated custody accounts with licensed financial institutions. Details of the reserves will be available to the public through regular independent attestation reports.  In July 2024, RD InnoTech Limited, the issuer of HKDR, was among the first batch of entities to be admitted to the stablecoin issuer sandbox by the Hong Kong Monetary Authority.  RD InnoTech Limited will abide stringently by the regulatory requirements for the launch of HKDR to contribute to the continuous development of Hong Kong as a global Web3 and virtual asset hub. For details about HKDR: https://rd.group/hkdr

Source: Hong Kong Government Press Release

Prime Focus Technologies expands Southeast Asia presence with strategic partnerships in Indonesia and the Philippines

LOS ANGELES, May 22, 2025 /PRNewswire/ — Prime Focus Technologies (PFT), the creator of CLEAR®, has entered strategic partnerships with Interindo Multimedia in Indonesia and Challenge Systems in the Philippines. These collaborations mark a significant step in PFT’s regional growth strategy, bringing its cutting-edge AI Agents and AI Applications closer to content companies across Southeast Asia, one of the world’s fastest-growing media and entertainment markets.

PFT partners with Interindo Multimedia in Indonesia and Challenge Systems in Philippines
PFT partners with Interindo Multimedia in Indonesia and Challenge Systems in Philippines

“SEA represents a fast-evolving landscape for content creation and distribution,” said Patricio Cummins, SVP & Global Head of Technology Sales at Prime Focus Technologies. “Southeast Asia is a rich tapestry of cultures and languages, where human connection drives business. From our collaboration with Tiara Vision in Malaysia to Interindo Multimedia and Challenge Systems in Indonesia and Philippines respectively, we’re proud to partner with some of the region’s most respected systems integrators. These alliances help us bring best-in-class AI solutions to content companies in SEA, delivering measurable impact across postproduction and content supply chains.”

PFT will showcase CLEAR® AI Agents and AI Applications delivering real results at Broadcast Asia 2025, Meeting Room #5J3-8, with live demonstrations.

About Interindo Multimedia

Interindo Multimedia is Indonesia’s premier broadcast technology partner, serving TV networks, cable operators, and DTH platforms. With decades of expertise and a focus on cutting-edge design, Interindo helps media businesses modernize their infrastructure and embrace future-ready technology.

Website: www.interindo.com

About Challenge Systems

Challenge Systems is a leading media technology partner in the Philippines. With deep roots in digital content creation and system integration, it delivers scalable, end-to-end solutions to broadcasters and enterprises nationwide.

Website: www.challenge.com.ph

About Prime Focus Technologies

Prime Focus Technologies (PFT) is the creator of CLEAR®. It offers streaming platforms, studios, and broadcasters AI technology and cloud media services—enabling creativity, agility, and most importantly, revenue growth. PFT partners with major players such as Channel 4, ITV, Sinclair Broadcast Group, A&E Networks, Warner Bros. Discovery, Paramount, Crunchyroll, Insight TV, JioStar, BCCI, Tegna, Amazon MGM Studios, and more.

For more information, visit: www.primefocustechnologies.com

Press Contact

T Shobhana
Senior Vice President & Global Head of Marketing
Prime Focus Technologies
Los Angeles, CA
t.shobhana@primefocus.com

 

Huntsman Corporation Announces New Purification and Packaging Capability through its E-GRADE® Unit in Conroe, Texas

THE WOODLANDS, Texas, May 22, 2025 /PRNewswire/ — Huntsman Corporation (NYSE: HUN), a global manufacturer and marketer of differentiated and specialty chemicals, is pleased to announce that its Performance Products division has expanded its manufacturing site in Conroe, Texas to better serve the growing needs of its global customers in the semiconductor industry.

Peter Huntsman, Chairman, President, and CEO of Huntsman Corporation, stated, “With the rapid growth of AI and the need for high-quality advanced node chips, our investment in Conroe marks our commitment to developing new semiconductor-grade products and enhancing supply chain security to support the demands of our customers worldwide.”

The new E-GRADE® unit will bolster Huntsman’s portfolio by providing high-purity, low-trace metal amines, including quaternary amines and amine oxides, essential for semiconductor chip manufacturing. Huntsman’s commitment to safety, quality, reliability, and manufacturing excellence will help ensure a consistent production process – from blending, purification through packaging.

“With this unique offering, we are well positioned to become a world-leading supplier of semiconductor-grade amines,” said Jan Buberl, President of Performance Products. “We now have the global manufacturing capability, R&D expertise, and broad portfolio to offer our customers with solutions that meet the industry’s highest quality standards.”

Conroe City Mayor, Duke Coon, commented, “Huntsman’s new E-GRADE® unit provides a significant boost for our local economy, helping to create numerous job opportunities and further solidifying Conroe’s position as a hub for advanced manufacturing and technology.”

About Huntsman:
Huntsman Corporation is a publicly traded global manufacturer and marketer of differentiated and specialty chemicals with 2024 revenues of approximately $6 billion. Our chemical products number in the thousands and are sold worldwide to manufacturers serving a broad and diverse range of consumer and industrial end markets. We operate more than 60 manufacturing, R&D and operations facilities in approximately 25 countries and employ approximately 6,300 associates within our continuing operations. For more information about Huntsman, visit the company’s website at  www.huntsman.com.                            

To learn more about E-GRADE® products, visit www.huntsman.com/EGRADE

Social Media:
LinkedIn:  www.linkedin.com/company/huntsman
X:  https://x.com/Huntsman_Corp
Facebook: 
www.facebook.com/huntsmancorp
Instagram: https://www.instagram.com/huntsman_corp/  

Huntsman Corporation Announces New Purification and Packaging Capability through its E-GRADE® Unit in Conroe, Texas
Huntsman Corporation Announces New Purification and Packaging Capability through its E-GRADE® Unit in Conroe, Texas

 

 

Prime Focus Technologies expands Southeast Asia presence with strategic partnerships in Indonesia and the Philippines

LOS ANGELES, May 22, 2025 /PRNewswire/ — Prime Focus Technologies (PFT), the creator of CLEAR®, has entered strategic partnerships with Interindo Multimedia in Indonesia and Challenge Systems in the Philippines. These collaborations mark a significant step in PFT’s regional growth strategy, bringing its cutting-edge AI Agents and AI Applications closer to content companies across Southeast Asia, one of the world’s fastest-growing media and entertainment markets.

PFT partners with Interindo Multimedia in Indonesia and Challenge Systems in Philippines
PFT partners with Interindo Multimedia in Indonesia and Challenge Systems in Philippines

“SEA represents a fast-evolving landscape for content creation and distribution,” said Patricio Cummins, SVP & Global Head of Technology Sales at Prime Focus Technologies. Southeast Asia is a rich tapestry of cultures and languages, where human connection drives business. From our collaboration with Tiara Vision in Malaysia to Interindo Multimedia and Challenge Systems in Indonesia and Philippines respectively, we’re proud to partner with some of the region’s most respected systems integrators. These alliances help us bring best-in-class AI solutions to content companies in SEA, delivering measurable impact across postproduction and content supply chains.”

PFT will showcase CLEAR® AI Agents and AI Applications delivering real results at Broadcast Asia 2025, Meeting Room #5J3-8, with live demonstrations.

About Interindo Multimedia

Interindo Multimedia is Indonesia’s premier broadcast technology partner, serving TV networks, cable operators, and DTH platforms. With decades of expertise and a focus on cutting-edge design, Interindo helps media businesses modernize their infrastructure and embrace future-ready technology.

Website: www.interindo.com

About Challenge Systems

Challenge Systems is a leading media technology partner in the Philippines. With deep roots in digital content creation and system integration, it delivers scalable, end-to-end solutions to broadcasters and enterprises nationwide.

Website: www.challenge.com.ph

About Prime Focus Technologies

Prime Focus Technologies (PFT) is the creator of CLEAR®. It offers streaming platforms, studios, and broadcasters AI technology and cloud media services—enabling creativity, agility, and most importantly, revenue growth. PFT partners with major players such as Channel 4, ITV, Sinclair Broadcast Group, A&E Networks, Warner Bros. Discovery, Paramount, Crunchyroll, Insight TV, JioStar, BCCI, Tegna, Amazon MGM Studios, and more.

For more information, visit: www.primefocustechnologies.com

Press Contact

T Shobhana
Senior Vice President & Global Head of Marketing
Prime Focus Technologies
Los Angeles, CA
t.shobhana@primefocus.com

Photo – https://laotiantimes.com/wp-content/uploads/2025/05/pr_sea-1.jpg 

Weichai’s M-series large-bore engines reinforce their leadership in the global premium power sector

SYDNEY, May 21, 2025 /PRNewswire/ — From May 16 to 18, Australia’s largest construction machinery exhibition — The National Diesel Dirt and Turf Expo (DDT) — grandly opened in Sydney. Weichai showcased its Baudouin M-series 6M33 pump diesel engine and 20M33 large-bore generator set at the event.

At the exhibition site, the 20M33 large-bore generator set showcased itself as a “high-performance beauty,” featuring a high-strength alloy steel crankshaft for enhanced structural integrity. Equipped with Weichai’s proprietary ECU system optimized through advanced algorithms, it demonstrates exceptional step-loading capabilities. The standard high-flow fuel filter extends oil change intervals, effectively reducing operational costs.

The 6M33 pump diesel engine also attracted crowds of clients at the event. Its critical components have undergone rigorous testing and market validation, ensuring high strength and reliability. Capable of operating in high-temperature environments up to 50°C, it has already accumulated over 12,000 hours of service in an Indonesian mine. With comprehensive system optimization, it achieves a minimum fuel consumption rate of 187.4 g/kWh.

Leveraging advantages such as ultra-low fuel consumption, excellent transient load response, and superior noise reduction capabilities, Weichai’s M-series large-bore engines have been widely adopted across diverse sectors including data centers, oil and gas, healthcare, high-altitude regions, railways, field rescue operations, and agriculture. The brand continues to strengthen its competitiveness in the global high-end power market.

Celltrion’s YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths

  • YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1]
  • Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled syringes (20mg & 80mg); Expanded interchangeability (IC) designation applies to prefilled syringe (40mg) and autoinjectors (40mg and 80mg)

INCHEON, South Korea, May 22, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA® (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations. With this approval, YUFLYMA is now fully interchangeable with the reference product, Humira® (adalimumab), across all marketed dosage forms and strengths.

YUFLYMA is a high-concentration, citrate-free biosimilar to Humira, approved for multiple inflammatory indications including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), ulcerative colitis (UC), plaque psoriasis (Ps), hidradenitis suppurativa (HS), and uveitis (UV) in adult patients; Crohn’s disease (CD) in adults and pediatric patients 6 years of age and older; and juvenile idiopathic arthritis (JIA) in patients 2 years of age and older.[1]

“This full interchangeability designation comes at a pivotal time as Celltrion continues to lead in the evolving biosimilar landscape,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “In alignment with recent federal initiatives aimed at lowering drug costs, we’ve taken timely action to enhance patient access and affordability. YUFLYMA – a high-concentration, citrate-free adalimumab biosimilar now fully interchangeable with Humira – reflects our long-standing commitment to delivering high-quality, accessible treatment options. Going forward, Celltrion will continue to put patients first by keeping drug costs affordable and remaining at the forefront of the U.S. biosimilar market, bringing competitive pricing and high-quality, accessible treatment options.”

The interchangeable designation builds on the Phase III interchangeability study, which demonstrated similar outcomes in terms of pharmacokinetics, efficacy, safety and immunogenicity in patients with moderately to severely active plaque psoriasis who received reference adalimumab (ADA) continuously and those who alternated between reference ADA and YUFLYMA during the dosing interval of Weeks 25-27. The result of the interchangeability study was presented at the European Academy of Dermatology & Venereology (EADV), September 2024, in the Netherlands.[2] 

The expanded interchangeability designation for YUFLYMA is complemented by a strategic price reduction that reflects Celltrion’s ongoing commitment to improving patient access while aligning with federal efforts to lower drug prices. Effective immediately, the wholesale acquisition cost (WAC) list price of YUFLYMA has been reduced to $948 per syringe, and the updated pricing has been uploaded to the national pricing compendia.

YUFLYMA was first introduced in the U.S. market in July 2023 and is currently available as a 20mg, 40mg, and 80mg solution for injection in prefilled syringes and as 40mg and 80mg in autoinjectors. Celltrion offers adalimumab-aaty in both branded and unbranded versions, with two pricing options to meet different patient needs and improve patient affordability.

Notes to Editors:

About YUFLYMA® (CT-P17, biosimilar adalimumab-aaty)[1]

YUFLYMA is a high-concentration, low-volume and citrate-free adalimumab biosimilar to receive European Commission approval. YUFLYMA is FDA approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis. YUFLYMA has been designated by the FDA as an interchangeable biosimilar in a prefilled syringe and autoinjector. YUFLYMA is a recombinant fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody. YUFLYMA is available in prefilled syringe as 20mg/0.2mL, 40mg/0.4mL and 80mg/0.8mL and autoinjector as 40mg/0.4mL and 80mg/0.8mL. Additionally, YUFLYMA features one of the longest shelf lives in its class, maintaining stability at room temperature (77 °F, 25 °C) for up to 31 days.

IMPORTANT SAFETY INFORMATION[1]This important safety information also applies to YUFLYMA® (adalimumab-aaty).

SERIOUS INFECTIONS

Patients treated with adalimumab-aaty are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue adalimumab-aaty if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before adalimumab-aaty use and during therapy. Initiate treatment for latent TB prior to adalimumab-aaty use.
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with adalimumab-aaty prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with adalimumab-aaty, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  • Treatment with adalimumab-aaty should not be initiated in patients with an active infection, including localized infections.
  • Patients over 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. Discontinue adalimumab-aaty if a patient develops a serious infection or sepsis. For a patient who develops a new infection during treatment with adalimumab-aaty, closely monitor them, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.
  • Drug interactions with biologic products: In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of adalimumab-aaty with abatacept or anakinra is not recommended in patients with RA. A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker. There is insufficient information regarding the concomitant use of adalimumab-aaty and other biologic products for the treatment of RA, PsA, AS, CD, UC, PS, and HS. Concomitant administration of adalimumab-aaty with other biologic disease-modifying antirheumatic drugs (DMARDs) (e.g., anakinra and abatacept) or other TNF blockers is not recommended based upon the possible increased risk for infections and other potential pharmacological interactions. A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to the use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.

  • Consider the risks and benefits of TNF blocker treatment including adalimumab-aaty prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC), or when considering continuing a TNF blocker in patients who develop a malignancy.
  • In controlled portions of clinical trials of some adalimumab products, more cases of malignancies have been observed compared to control-treated adult patients.
  • NMSC was reported during clinical trials for patients treated with adalimumab products. During the controlled portions of 39 global adalimumab clinical trials in adult patients with RA, PsA, AS, CD, UC, PS, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, 1.09) per 100 patient-years among adalimumab-treated patients and 0.2 (0.10, 0.59) per 100 patient-years among control-treated patients. Examine all patients, particularly those with a medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a history of psoralen + ultraviolet light A (PUVA) treatment, for the presence of NMSC prior to and during treatment with adalimumab-aaty.
  • In clinical trials of some adalimumab products, there was an approximately threefold higher rate of lymphoma than expected in the general U.S. population. Patients with RA and other chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to severalfold) than the general population for the development of lymphoma, even in the absence of TNF blockers.
  • Postmarketing cases of acute and chronic leukemia were reported with the use of a TNF blocker in RA and other indications. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving adalimumab were lymphomas; other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.

HYPERSENSITIVITY

  • Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of adalimumab-aaty and institute appropriate therapy.

HEPATITIS B VIRUS REACTIVATION

  • Use of TNF blockers, including adalimumab-aaty, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.
  • Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.
  • Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV and closely monitor such patients for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy.
  • In patients who develop HBV reactivation, stop adalimumab-aaty and initiate effective antiviral therapy with appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV reactivation is controlled is not known. Therefore, exercise caution when considering resumption of adalimumab-aaty therapy in this situation and monitor patients closely.

NEUROLOGIC REACTIONS

  • Use of TNF blocking agents, including adalimumab products, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome.
  • Exercise caution in considering the use of adalimumab-aaty in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of adalimumab-aaty should be considered if any of these disorders develop.
  • There is a known association between intermediate uveitis and central demyelinating disorders.

HEMATOLOGIC REACTIONS

  • Rare reports of pancytopenia including aplastic anemia have been reported with TNF blocking agents.
  • Adverse reactions of the hematologic system, including medically significant cytopenia, have been infrequently reported with adalimumab products.
  • Consider discontinuation of adalimumab-aaty therapy in patients with confirmed significant hematologic abnormalities.

HEART FAILURE

  • Cases of worsening congestive heart failure (CHF) and new-onset CHF have been reported with TNF blockers. Cases of worsening CHF have also been observed with adalimumab products.
  • Exercise caution when using adalimumab-aaty in patients who have heart failure and monitor them carefully.

AUTOIMMUNITY

  • Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with adalimumab-aaty, discontinue treatment.

IMMUNIZATIONS

  • Patients on adalimumab-aaty may receive concurrent vaccinations, except for live vaccines.
  • It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating adalimumab-aaty therapy.
  • No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab products.
  • The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS

  • The most common adverse reactions in adalimumab clinical trials (>10%) were infections (e.g., upper respiratory, sinusitis), injection site reactions, headache, and rash.

INDICATIONS

Adalimumab-aaty is a tumor necrosis factor (TNF) blocker indicated for:

  • Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA
  • Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older
  • Psoriatic Arthritis (PsA): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA
  • Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS
  • Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
  • Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adults Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers
  • Plaque Psoriasis (Ps): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
  • Hidradenitis Suppurativa (HS): treatment of adult patients with moderate to severe hidradenitis suppurativa
  • Uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients

For Yuflyma (adalimumab-aaty): Please click for Full U.S. Prescribing Information.

For adalimumab-aaty: Please see Full U.S. Prescribing Information.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About Celltrion, Inc.

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us  and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion’s FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (ustekinumab-stba), STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo) and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipate” the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

Humira is a registered trademark of AbbVie.

YUFLYMA® is a registered trademark of Celltrion, Inc., used under license.

References

[1] YUFLYMA US prescribing information (2023)

[2] Lebwohl M et al., Pharmacokinetics, Efficacy and Safety after Multiple Switches from Reference Adalimumab to Adalimumab Biosimilar (CT-P17) in comparison with the Maintenance Group (Reference Adalimumab) in Patients with Moderate-toSevere Plaque Psoriasis: Week 27 Results from the Phase III Interchangeability Study. [EADV 2024, Poster number P0931]. Available at:

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eadv/abstracts_congress_2024/41489.pdf

For further information please contact: 
Andria Arena
aarena@jpa.com
+1 516-578-0057

Dave & Buster’s Breaks Ground on First Location in the Philippines at Opus Mall

MANILA, Philippines, May 22, 2025 /PRNewswire/ — Dave & Buster’s has officially broken ground on its first location in the Philippines, marking a major milestone in its global expansion. Located at the vibrant Opus Mall in Manila, the new venue will introduce Dave & Buster’s unique blend of games, food, and sports viewing to the Filipino market.

Dave & Buster's Breaks Ground on First Location in the Philippines at Opus Mall
Dave & Buster’s Breaks Ground on First Location in the Philippines at Opus Mall

The groundbreaking ceremony, held in partnership with local franchisee The Bistro Group, welcomed company executives, local officials, and community leaders. This flagship venue is poised to become a premier destination for immersive entertainment, dynamic sports viewing, and craveable American fare.

“This is more than a groundbreaking—it’s a landmark moment in our international story,” said Antonio Bautista, Chief International Development Officer for Dave & Buster’s. “With the strength of our partnership with The Bistro Group, we’re bringing an exciting new concept to Manila that delivers fun, flavor, and unforgettable experiences.”

Jean Paul Manuud, President of The Bistro Group, added: “Dave & Buster’s is a game-changing brand. We’re proud to launch this first-of-its-kind experience in the Philippines where great food, cutting-edge games, and community come together.”

The Manila location will feature a curated mix of American classics and localized dishes, state-of-the-art games, and multi-use spaces for events and sports fans. This opening kicks off a broader multi-unit development plan in the country.

This milestone reinforces Dave & Buster’s commitment to international growth, with additional venues planned this year in India (second location), Australia, Mexico, and the Dominican Republic. The brand currently operates over 220 locations across North America and is now expanding across five continents.

About Dave & Buster’s
Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster’s Entertainment, Inc. operates leading entertainment and dining venues across North America under the Dave & Buster’s and Main Event brands. For more information, visit www.daveandbusters.com.

About The Bistro Group
The Bistro Group is a leading restaurant operator in the Philippines, known for introducing iconic international brands like TGIFridays, Denny’s, Texas Roadhouse, and Hard Rock Café to the local market. For more information, visit www.bistro.com.ph.